Charles Schwab Investment Management Inc Biotechnology

Charles Schwab Investment Management Inc

$527 Billion
Q4 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
VRTX Vertex Pharmaceuticals Inc	$126B	$670 Million 0.13% of portfolio	1,663,849	Q4 2024 Added 2.31%
REGN Regeneron Pharmaceuticals, Inc.	$73.7B	$496 Million 0.09% of portfolio	695,799	Q4 2024 Added 3.35%
UTHR United Therapeutics Corp	$14.2B	$131 Million 0.02% of portfolio	370,540	Q4 2024 Added 0.16%
ALNY Alnylam Pharmaceuticals, Inc.	$30.7B	$121 Million 0.02% of portfolio	513,962	Q4 2024 Added 5.46%
INCY Incyte Corp	$15.5B	$113 Million 0.02% of portfolio	1,643,067	Q4 2024 Added 2.1%
PCVX Vaxcyte, Inc.	$4.38B	$110 Million 0.02% of portfolio	1,341,773	Q4 2024 Added 3.54%
EXEL Exelixis, Inc.	$12.4B	$108 Million 0.02% of portfolio	3,252,353	Q4 2024 Reduced 0.65%
INSM Insmed Inc	$10.5B	$107 Million 0.02% of portfolio	1,546,607	Q4 2024 Added 7.09%
TECH Bio Techne Corp	$2.44B	$106 Million 0.02% of portfolio	1,465,690	Q4 2024 Added 3.66%
MRNA Moderna, Inc.	$13.8B	$97.5 Million 0.02% of portfolio	2,344,203	Q4 2024 Added 9.91%
BMRN Biomarin Pharmaceutical Inc	$13.2B	$93.6 Million 0.02% of portfolio	1,423,508	Q4 2024 Added 1.56%
HALO Halozyme Therapeutics, Inc.	$8.29B	$85.3 Million 0.02% of portfolio	1,783,177	Q4 2024 Added 0.55%
RVMD Revolution Medicines, Inc.	$3.47B	$84.5 Million 0.02% of portfolio	1,931,114	Q4 2024 Added 9.53%
RPRX Royalty Pharma PLC	$14.8B	$79.9 Million 0.02% of portfolio	3,131,628	Q4 2024 Added 4.33%
SRPT Sarepta Therapeutics, Inc.	$9.43B	$75.8 Million 0.01% of portfolio	623,749	Q4 2024 Added 1.96%
JAZZ Jazz Pharmaceuticals PLC	$8.79B	$75.8 Million 0.01% of portfolio	615,517	Q4 2024 Added 15.76%
CYTK Cytokinetics Inc	$4.13B	$62.8 Million 0.01% of portfolio	1,335,189	Q4 2024 Added 1.04%
CORT Corcept Therapeutics Inc	$5.94B	$53 Million 0.01% of portfolio	1,051,560	Q4 2024 Added 2.44%
BPMC Blueprint Medicines Corp	$5.37B	$52.7 Million 0.01% of portfolio	604,397	Q4 2024 Added 1.2%
IONS Ionis Pharmaceuticals Inc	$4.79B	$51.8 Million 0.01% of portfolio	1,481,440	Q4 2024 Added 2.66%
MDGL Madrigal Pharmaceuticals, Inc.	$5.94B	$46.5 Million 0.01% of portfolio	150,746	Q4 2024 Added 1.88%
ADMA Adma Biologics, Inc.	$3.34B	$41.9 Million 0.01% of portfolio	2,440,294	Q4 2024 Added 1.61%
CRNX Crinetics Pharmaceuticals, Inc.	$1.82B	$38.8 Million 0.01% of portfolio	759,126	Q4 2024 Added 15.82%
TGTX Tg Therapeutics, Inc.	$5.17B	$38.2 Million 0.01% of portfolio	1,269,513	Q4 2024 Added 7.17%
KRYS Krystal Biotech, Inc.	$4.62B	$38.1 Million 0.01% of portfolio	243,170	Q4 2024 Added 1.23%
BBIO Bridge Bio Pharma, Inc.	$5.18B	$35.9 Million 0.01% of portfolio	1,306,765	Q4 2024 Added 1.71%
ROIV Roivant Sciences Ltd.	$7.54B	$33.3 Million 0.01% of portfolio	2,812,502	Q4 2024 Added 1.63%
APLS Apellis Pharmaceuticals, Inc.	$2.86B	$31.8 Million 0.01% of portfolio	996,748	Q4 2024 Added 4.22%
PTCT Ptc Therapeutics, Inc.	$3.72B	$31 Million 0.01% of portfolio	685,709	Q4 2024 Reduced 2.97%
RNA Avidity Biosciences, Inc.	$1.49B	$29.9 Million 0.01% of portfolio	1,028,931	Q4 2024 Added 3.91%
VKTX Viking Therapeutics, Inc.	$2.15B	$29.3 Million 0.01% of portfolio	728,652	Q4 2024 Added 1.82%
VCYT Veracyte, Inc.	$2.36B	$28.6 Million 0.01% of portfolio	720,969	Q4 2024 Reduced 1.91%
CRSP Crispr Therapeutics Ag	$3.42B	$28.5 Million 0.01% of portfolio	723,032	Q4 2024 Reduced 0.17%
AXSM Axsome Therapeutics, Inc.	$5.36B	$27.8 Million 0.01% of portfolio	328,034	Q4 2024 Added 1.69%
SRRK Scholar Rock Holding Corp	$1.92B	$26.9 Million 0.01% of portfolio	622,409	Q4 2024 Added 23.79%
SMMT Summit Therapeutics Inc.	$3.73B	$26.5 Million 0.01% of portfolio	1,485,072	Q4 2024 Added 3.65%
ACLX Arcellx, Inc.	$2.88B	$26.1 Million 0.0% of portfolio	343,085	Q4 2024 Added 4.57%
CPRX Catalyst Pharmaceuticals, Inc.	$2.27B	$26 Million 0.0% of portfolio	1,246,925	Q4 2024 Added 6.78%
RARE Ultragenyx Pharmaceutical Inc.	$2.86B	$25.8 Million 0.0% of portfolio	613,633	Q4 2024 Added 3.21%
NUVL Nuvalent, Inc.	$3.08B	$25.3 Million 0.0% of portfolio	323,569	Q4 2024 Added 2.45%
VCEL Vericel Corp	$2.43B	$24.8 Million 0.0% of portfolio	451,464	Q4 2024 Added 3.97%
RYTM Rhythm Pharmaceuticals, Inc.	$2.97B	$24.6 Million 0.0% of portfolio	440,250	Q4 2024 Added 1.47%
FOLD Amicus Therapeutics, Inc.	$2.57B	$24.4 Million 0.0% of portfolio	2,586,803	Q4 2024 Reduced 3.02%
ACAD Acadia Pharmaceuticals Inc	$2.93B	$23 Million 0.0% of portfolio	1,251,332	Q4 2024 Reduced 1.56%
PTGX Protagonist Therapeutics, Inc	$1.9B	$22.3 Million 0.0% of portfolio	578,409	Q4 2024 Added 2.28%
SWTX Spring Works Therapeutics, Inc.	$3.16B	$21.9 Million 0.0% of portfolio	605,248	Q4 2024 Added 0.5%
BNTX Bio N Tech Se	$27.9B	$21.3 Million 0.0% of portfolio	187,355	Q4 2024 Added 39.78%
DNLI Denali Therapeutics Inc.	$2.19B	$21 Million 0.0% of portfolio	1,028,462	Q4 2024 Added 1.25%
NVO Novo Nordisk A S	$205B	$19.4 Million 0.0% of portfolio	225,914	Q4 2024 Added 10.43%
ARWR Arrowhead Pharmaceuticals, Inc.	$1.84B	$19.1 Million 0.0% of portfolio	1,017,720	Q4 2024 Added 1.07%

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.